EVRY, France, April 19 /PRNewswire/ -- Novagali Pharma, an emerging ophthalmic pharmaceutical company, announced today the appointment of Philippe Garcia as Chief Financial Officer.
Philippe Garcia has more than 15 years of experience in the industry, including the health sector serving the last 5 years as Chief Financial Officer of Floreane Medical implants, a company specialized in surgical implants listed on Euronext (Paris, Eurolist C) where he participated to the industrial growth and international expansion of the company (2002-2007). He started his career as financial auditor at cabinet Deloitte & Touche (1990-1997) and was then subsequently Chief Financial Officer of the European Industrial Products division of US BF Goodrich group (1997-2001) and Chief financial Officer of EuroCave Group (2001-2002).
“I am delighted that Philippe has joined our team to play a critical role in our move to a fully Integrated Specialty Pharma Company,” declared Jerome Martinez, President and CEO of Novagali Pharma who added “His financial track record of successfully delivering enhanced performance and shareholder value will play a pivotal part in Novagali continued development”.
Philippe Garcia followed “I am very pleased to join a dynamic team with an impressive list of major achievements, sharing my experience of a listed company to support the rapid growth of Novagali’s activities”.
A Certified Public Accountant, Philippe Garcia, 43, is graduated from Lyon University where he earned a Master of Accounting and Financial Management. He also received an extensive training in International Financial Reporting Standards and Sarbanes-Oxley compliance.
About Novagali Pharma: www.novagali.com
Novagali Pharma SA is an emerging ophthalmic pharmaceutical company based in the Genopole biocluster in Evry, France, that develops innovative products for all segments of the eye. Thanks to its proprietary technology platforms Novasorb(R) and Eyeject(R), the company has developed a broad pipeline of innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia(R), an orphan product for treatment of vernal keratoconjunctivitis; Cationorm(R), a CE marking product for dry eye relief; and Nova22007, a product for the treatment of moderate-to-severe dry eye syndrome. Founded in 2000, the firm has raised a total amount of Euro 44 million in 3 series of financing.
Press Contact: Genevieve Garrigos +33(0)1-69-87-40-20 genevieve.garrigos@novagali.com
Nova Gali Pharma
CONTACT: Press Contact: Genevieve Garrigos, +33(0)1-69-87-40-20,genevieve.garrigos@novagali.com
